Talquetamab: Myeloma Treatment & CAR T-Cell Therapy
:
A New Hope for Multiple Myeloma: Bridging to CAR-T Therapy with Talquetamab
For patients battling multiple myeloma, a blood cancer that remains challenging to treat, a new strategy is offering hope. Researchers are exploring the use of talquetamab, a bispecific antibody, as a “bridge” to CAR-T cell therapy, potentially improving outcomes and expanding access to this powerful treatment.
CAR-T cell therapy, where a patient’s own immune cells are engineered to target and destroy cancer cells, has shown remarkable success in certain specific cases of multiple myeloma.However, not all patients are promptly eligible. A high disease burden – meaning a large amount of cancer in the body – can compromise a patient’s health and make them unsuitable candidates for the intensive CAR-T process.
This is where talquetamab comes in. Recent studies suggest that administering talquetamab before CAR-T cell therapy can effectively reduce the tumor load, making more patients eligible and potentially improving the safety and efficacy of the subsequent CAR-T infusion. the approach involves sequentially targeting the cancer with two different mechanisms: first with talquetamab, which targets the GPRC5D protein on myeloma cells, and then with CAR-T cells, which target BCMA. This dual attack aims to eradicate as much of the cancer as possible.
“The core finding is that talquetamab can act as a bridge, allowing patients to achieve better disease control, which in turn can lead to more favorable outcomes with subsequent CAR-T cell therapy,” explains Dr. Binod Dhakal, an associate professor of medicine at the Medical College of Wisconsin.The research,involving data from 119 patients across 20 centers (18 in the US and 2 in Germany),has been encouraging. Importantly, the study showed no evidence of delayed toxicities, such as Parkinsonism or Guillain-Barré syndrome, in patients followed for at least seven months. This raises the question of whether talquetamab might even have a protective effect, making CAR-T therapy safer.
While the initial results are promising, further research is needed to confirm whether the sequential approach truly reduces the risk of side effects associated with CAR-T cell therapy. Researchers are now investigating whether this strategy is beneficial for all patients, or primarily those with a high disease burden.
This innovative approach represents a significant step forward in the fight against multiple myeloma, offering a potential pathway to more effective and accessible treatment for a wider range of patients. The hope is that by combining these therapies,doctors can not only improve outcomes but also enhance the quality of life for those living with this challenging cancer.